Business Context and Reporting Period
This Form 8-K is a current report filed by WellPoint, Inc. (now Elevance Health, Inc.) on September 12, 2011. The filing serves as a Regulation FD disclosure regarding upcoming communications between company officers and securities analysts/investors scheduled between September 13, 2011, and September 26, 2011.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity figures for the current or prior periods. The only specific financial metric disclosed is the forward-looking earnings per share (EPS) guidance.
- Full Year 2011 EPS Guidance: $6.90 to $7.10 per share.
- Net Investment Gains Included: $0.15 per share.
- Investment Outlook Assumption: No additional investment gains or losses beyond those recorded in the first two quarters of 2011.
Material Changes
The filing does not report material changes to financial results, operations, or corporate structure compared to prior periods. It solely confirms the reaffirmation of previously issued guidance.
Guidance, Outlook, and Risks
Management expects to reaffirm the full-year 2011 EPS range of $6.90 to $7.10. The filing includes an extensive "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995, identifying numerous risks that could cause actual results to differ materially from projections. Key risks include:
- Impact of the Patient Protection and Affordable Care Act and related regulations.
- Trends in health care costs, utilization rates, and premium rate approvals.
- Competitor pricing and changes in product mix or enrollment.
- Risks associated with Medicare and Medicaid programs, including funding and compliance.
- Financial strength rating downgrades and litigation outcomes.
- Operational risks regarding the Express Scripts, Inc. agreement and information systems.
- Market conditions affecting investment portfolios and liquidity.
- General economic downturns and public health catastrophes.
Investor Verification Checklist
- Verify the actual full-year 2011 EPS against the $6.90 to $7.10 guidance range.
- Confirm the realization of the $0.15 per share net investment gain assumption.
- Monitor regulatory developments regarding the Affordable Care Act and their impact on premium rates.
- Review subsequent filings for updates on litigation, investigations, or financial strength ratings.
- Assess the status of the Express Scripts, Inc. pharmacy benefit management agreement.